



# NRG Oncology Presentation Schedule

Oral, Quick Pitch Oral, Poster, and Educational Presentations

**OCTOBER 1-4, 2023**

Disease Site & Study #	Sunday, October 1, 2023	Time/Location
Genitourinary-Prostate NRG/RTOG 0415	<p><b>Title:</b> <i>Long-term follow-up analysis of NRG oncology RTOG 0415: a randomized phase III non-inferiority study comparing 2 fractionation schedules in patients with favorable-risk prostate cancer</i></p> <p><b>Presenter:</b> W. Robert Lee, MD</p> <p><b>Abstract #:</b> 6</p>	<p><b>Location:</b> San Diego Convention Center, Ballroom 20</p> <p><b>Session:</b> CT 01: Clinical Trials Session</p> <p><b>Date:</b> Sunday, October 1, 2023</p> <p><b>Time:</b> 10:00AM – 10:10AM</p> <p><b>Duration:</b> 10-min</p> <p><b>Oral Presentation</b></p>
Prostate NRG/RTOG 0126	<p><b>Title:</b> <i>Long-Term Outcomes of NRG/RTOG 0126, A Randomized Trial of High Dose (79.2Gy) vs. Standard Dose (70.2Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer</i></p> <p><b>Presenter:</b> Jeff Michalski, MD</p> <p><b>Abstract #:</b> 7</p>	<p><b>Location:</b> San Diego Convention Center, Ballroom 20</p> <p><b>Session:</b> CT 01: Clinical Trials Session</p> <p><b>Date:</b> Sunday, October 1, 2023</p> <p><b>Time:</b> 10:10AM – 10:20AM</p> <p><b>Duration:</b> 10-min</p> <p><b>Oral Presentation</b></p>
	<p><i>Beyond RTOGv2.0: The First Ten Years of NRG Oncology and Paying It Forward for Many Years Ahead</i></p> <p><b>Session Chairs:</b> Quynh Le, MD and Mitch Machtay</p> <p><b>Speakers:</b> Kristin Higgins, MD and Vinai Gondy, MD</p>	<p><b>Location:</b> Room 30 A/B/C</p> <p><b>Date:</b> Sunday, October 1, 2023</p> <p><b>Time:</b> 4:57PM - 5:17PM</p> <p><b>Master Class</b></p> <p>\$25-Members/Nonmembers \$0-Students/Residents/Fellows</p>
Disease Site & Study #	Monday, October 2, 2023	Time/Location
Genitourinary-Bladder NRG/RTOG 0524 NRG/RTOG 0712	<p><b>Title:</b> <i>Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: analysis of NRG RTOG 0524 and 0712</i></p> <p><b>Presenter:</b> Matthew Deek, MD</p> <p><b>Abstract #:</b> 136</p>	<p><b>Location:</b> Room 4</p> <p><b>Session:</b> SS 07 - Bio 2: Genomics, Biomarkers, and Tumor Biology</p> <p><b>Date:</b> Monday, October 2, 2023</p> <p><b>Time:</b> 8:30AM-8:37AM</p> <p><b>Duration:</b> 7-minutes</p> <p><b>Oral Presentation</b></p>
Genitourinary-Prostate NRG/RTOG 0534	<p><b>Title:</b> <i>Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORT</i></p> <p><b>Presenter:</b> Deborah Bruner, MD</p> <p><b>Abstract #:</b> 139</p>	<p><b>Location:</b> Room 6 C/F</p> <p><b>Session:</b> SS 08 - GU 2: Clinical Trials in Prostate Cancer</p> <p><b>Date:</b> Monday, October 2, 2023</p> <p><b>Time:</b> 10:45AM - 10:52AM.</p> <p><b>Duration:</b> 7-min</p> <p><b>Oral Presentation</b></p>
Head & Neck NRG/RTOG 1016	<p><b>Title:</b> <i>Hearing outcomes in cisplatin or cetuximab combined with radiation for patients with HPV-associated oropharyngeal cancer in NRG/RTOG 1016</i></p> <p><b>Presenter:</b> Christina Runge, PhD</p> <p><b>Abstract #:</b> 1052</p>	<p><b>Location:</b> Room 7</p> <p><b>Session:</b> QP 05 - H&amp;N 1: Optimizing Patient-Centered Quality of Life and Function</p> <p><b>Time:</b> 11:00AM - 11:05AM</p> <p><b>Duration:</b> 5-minutes</p> <p><b>Quick Pitch</b></p>
Lung, Brain NRG-CC003	<p><b>Title:</b> <i>Primary endpoint results of NRG CC003: Phase IIR/III trial of prophylactic cranial irradiation (PCI) with or without hippocampal avoidance (HA) for small cell lung cancer (SCLC)</i></p> <p><b>Presenter:</b> Vinai Gondy, MD</p> <p><b>Abstract #:</b> LBA 04</p>	<p><b>Location:</b> San Diego Convention Center, Ballroom 20</p> <p><b>Session:</b> PL 01: Plenary Session</p> <p><b>Date:</b> Monday, October 2, 2023</p> <p><b>Time:</b> 1:30PM – 1:40PM</p> <p><b>Duration:</b> 10-min</p> <p><b>Plenary Session</b></p>

Genitourinary-Prostate NRG/RTOG 0521	<b>Title:</b> <i>Validation of a genomic classifier in the NRG Oncology/RTOG 0521 phase III trial of docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer.</i> <b>Presenter:</b> Ryan Phillips, MD <b>Abstract #:</b> 158	<b>Location:</b> Room 6 D/E <b>Session:</b> SS 11-GU 3: Novel Prognostication Techniques for Prostate Cancer <b>Date:</b> Monday, October 2, 2023 <b>Time:</b> 3:10PM – 3:17PM <b>Duration:</b> 7-min <b>Oral Presentation</b>
Lung NRG/RTOG 0617, NRG-LU001	<b>Title:</b> <i>Progression-free survival as a surrogate endpoint of overall survival in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy: trial-level meta-analysis and individual-level analysis of NRG/RTOG 0617 and PROCLAIM</i> <b>Presenter:</b> Chen Hu, PhD <b>Abstract #:</b> 1074	<b>Location:</b> Room 8 <b>Session:</b> QP 07: Lung 2: Immune Checkpoint Inhibition (ICI): Incorporation into SCLC Management; Impacts on Toxicity for LA-NSCLC <b>Date:</b> Monday, October 2, 2023 <b>Time:</b> 5:10PM - 5:15PM <b>Duration:</b> 5-minutes <b>Quick Pitch</b>
Head & Neck NRG/RTOG 0920	<b>Title:</b> <i>Randomized phase III trial of postoperative radiotherapy with or without cetuximab for intermediate-risk squamous cell carcinoma of the head and neck (SCCHN): NRG/RTOG 0920</i> <b>Presenter:</b> Mitchell Machtay, MD <b>Abstract #:</b> LBA 01	<b>Location:</b> San Diego Convention Center, Ballroom 20 <b>Session:</b> PL 01: Plenary Session <b>Date:</b> Monday, October 2, 2023 <b>Time:</b> 1:30PM - 3:00PM <b>Duration:</b> 10-min <b>Plenary Session</b>
<b>Disease Site &amp; Study #</b>	<b>Tuesday, October 3, 2023</b>	<b>Time/Location</b>
Head & Neck NRG/RTOG 1016	<b>Title:</b> <i>The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer in NRG/RTOG 1016</i> <b>Presenter:</b> Joanne Weidhaas, PhD <b>Abstract #:</b> 1172	<b>Location:</b> Room 4 <b>Session:</b> QP 16 - H&N 3: Innovative Approaches to Individualizing Therapy for Head & Neck and Skin Cancer <b>Date:</b> Tuesday, October 3, 2023 <b>Time:</b> 5:25PM - 5:30PM <b>Duration:</b> 5-min <b>Quick Pitch</b>
Genitourinary-Prostate NRG/RTOG 0534	<b>Title:</b> <i>Impact of testosterone recovery on clinical outcomes of patients treated with salvage radiotherapy and androgen suppression: a secondary analysis of the NRG/RTOG 0534 SPPORT phase 3 trial</i> <b>Presenter:</b> Alan Dal Pra, MD <b>Abstract #:</b> 261	<b>Location:</b> Room 6 B <b>Session:</b> SS 28 - GU 4: Radiotherapy for Kidney Cancer and Post-Prostatectomy <b>Date:</b> Tuesday, October 3, 2023 <b>Time:</b> 5:35PM – 5:42 PM <b>Duration:</b> 7-min <b>Oral Presentation</b>
<b>Disease Site &amp; Study #</b>	<b>The following presentations include NRG author/investigators from NCTN sponsored federal trials, and NSABP-RTOG-GOG Foundation studies</b>	<b>Time/Location</b>
Brain NRG-CC001	<b>Title:</b> <i>Estimation of Conditional Neurocognitive Function Failure (NCFF) Incidence in Patients Receiving Whole Brain Radiation Therapy (WBRT) for Brain Metastases (BM): Secondary Analysis of NRG CC001</i> <b>Presenter:</b> Hua-Ren Cherng, MD <b>Poster Bd #:</b> 2208	<b>Location:</b> Hall B2 <b>Session:</b> PQA 02 - Poster Q&A 02 - Central Nervous System and Palliative Care <b>Date:</b> Monday, October 2, 2023 <b>Time:</b> 10:45AM – 12:00PM <b>Duration:</b> 75-min <b>Poster</b>
Brain & Spine NRG/RTOG 9006	<b>Title:</b> <i>Conditional Survival Estimates for Malignant Glioma Patients by RPA Class: Secondary Analysis of RTOG 9006</i> <b>Presenter:</b> Matthew Brown, MD <b>Poster Bd #:</b> 2200	<b>Location:</b> Hall B2 <b>Session:</b> PQA 02 - Poster Q&A 02 - Central Nervous System and Palliative Care <b>Date:</b> Monday, October 2, 2023 <b>Time:</b> 10:45AM – 12:00PM <b>Duration:</b> 75-min <b>Poster</b>

Prostate NRG/RTOG 0126	<b>Title:</b> <i>Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126</i> <b>Presenter:</b> Gregory Alexander, MD <b>Abstract #:</b> 283	<b>Location:</b> Room 1 <b>Session:</b> SS 32 - GU 5: Patient-Reported Quality of Life in Prostate Cancer <b>Date:</b> Wednesday, October 4, 2023 <b>Time:</b> 10:50AM – 10:57AM <b>Duration:</b> 7-min <b>Oral Presentation</b>
Head & Neck NRG/RTOG 1016	<b>Title:</b> <i>Effectiveness of Cisplatin in P16+ Oropharyngeal Cancer According to Relative Risk for Cancer Events: Ancillary Analysis of RTOG 1016</i> <b>Presenter:</b> Loren Mell, MD, FASTRO <b>Abstract #:</b> 233	<b>Location:</b> Room 1 <b>Session:</b> SS 23 - H&N 2: Virus-Associated Head & Neck Cancers: From Screening to Treatment <b>Date:</b> Tuesday, October 3, 2023 <b>Time:</b> 2:50PM – 2:57PM <b>Duration:</b> 7-min <b>Oral Presentation</b>